Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
Go back to Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation| Edwards Lifesciences (NYSE: EW) | Delayed: 88.34 +0.08 (0.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $88.26 | 52 Week High | $166.87 | |||
| Open | $88.34 | 52 Week Low | $72.20 | |||
| Day High | $88.59 | P/E | 25.68 | |||
| Day Low | $87.77 | EPS | $3.44 | |||
| Volume | 3,347,112 | |||||
